Activated Islet Proliferating Cells for Rapid Insulin Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating insulin-producing pancreatic beta cells for diabetes treatment are inefficient, requiring multiple genetic manipulations, long culture periods, and are prone to contamination and high production costs, limiting their clinical translation.
Innovation Solution
The development of an activated islet proliferating cell (AIPC) population and a method to rapidly differentiate isolated pancreatic islets into insulin-producing cells using a culture medium with an active agent, such as a polypeptide with specific amino acid sequences, which promotes cell expansion and glucose responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard techniques (genetic reprogramming, differentiation factors, therapeutic molecules) are used to generate beta cells, then insulin-producing cells can be obtained, but the process requires long culture periods, multiple manipulation steps, and is prone to microbiological contamination
Solution Approach 1:
The patent uses activated islet proliferating cells (AIPCs) that have been pre-activated ex vivo before transplantation. These AIPCs are prepared in advance with enhanced proliferative capacity through specific culture conditions, allowing them to rapidly expand after implantation rather than requiring long in vitro culture periods. This preliminary activation resolves the contradiction by preparing cells beforehand without requiring extended culture time that would increase contamination risk.
Solution Approach 2:
The AIPC population possesses intrinsic self-proliferation capabilities that are activated after transplantation. Rather than requiring continuous external manipulation and long-term culture, the cells autonomously expand and differentiate in the physiological environment, reducing the need for prolonged laboratory culture and associated contamination risks while maintaining high success rates.
2Reliability
If multiple genetic manipulations and differentiation factors are applied, then beta cell differentiation can be achieved, but production costs increase significantly
Solution Approach 1:
The patent extracts and utilizes specific growth factors and signaling molecules (such as IGF-1, FGF-2, and other mitogenic factors) that naturally promote islet cell proliferation, separating these key elements from complex multi-factor differentiation protocols. By focusing on a streamlined set of proliferative signals rather than comprehensive differentiation factor cocktails, the method reduces production costs while maintaining effective cell generation for therapy.
Solution Approach 2:
The invention changes the cultural parameters from differentiation-focused conditions to proliferation-focused conditions. AIPCs are cultured in media optimized for cell division rather than differentiation, using specific growth factors and conditions that promote expansion. This parameter shift reduces the need for expensive differentiation factors and genetic manipulations while achieving the therapeutic goal of generating sufficient insulin-producing cells.
3Quantity of substance
If islet cells are maintained in culture for extended periods, then cell expansion can occur, but cells deteriorate and cannot be maintained long-term
Solution Approach 1:
The patent prepares AIPCs ex vivo with enhanced proliferative potential before transplantation, rather than attempting long-term in vitro maintenance. This preliminary preparation allows cells to be expanded to adequate numbers under optimized short-term conditions, then transferred to the physiological environment where they continue to proliferate and survive without the deterioration that occurs in extended culture.
Solution Approach 2:
AIPCs possess inherent properties that allow them to self-maintain and proliferate in the physiological environment after transplantation. The cells activate their own survival and proliferation programs in vivo, avoiding the deterioration that occurs during extended in vitro culture. This self-service capability enables long-term viability without requiring continuous laboratory maintenance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid expansion of insulin-producing cells that are glucose responsive and capable of long-term culture, potentially addressing the limitations of current beta cell generation methods and providing a viable source for cell-based therapies.
Implementation Method 1
rapidly differentiate isolated pancreatic islets into insulin-producing cells
Implementation Method 2
enables the rapid expansion of insulin-producing cells
Implementation Method 3
insulin-producing cells that are glucose responsive
Data Source
AI summary
Disclosed herein are compositions and methods to differentiate pancreatic cells into functional insulin-producing CD133/Ki-67-positive activated islet proliferating cells (AIPCs) derived from isolated pancreatic islets and expand derived-AIPCs in in vitro cultures using a culture medium comprising an active agent. Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.